Melanoma
Pipeline by Development Stage
Drug Modality Breakdown
Melanoma is a $1.4B market at peak maturity, dominated by targeted therapies and checkpoint inhibitors with established standard-of-care regimens.
Key Trends
- Targeted BRAF/MEK inhibitor combinations remain market leaders (Novartis, Pfizer) with $407M combined spending
- Checkpoint inhibitors (PD-1/CTLA-4) gaining share as adjuvant and combination therapies expand
- Significant patent cliff risk: MEKINIST loses exclusivity April 2031 ($173M revenue exposure)
Career Verdict
Solid but stabilizing market—good for commercial, clinical operations, and MSL roles seeking established disease expertise; limited growth upside for R&D unless you target resistance mechanisms or rare subtypes.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | MEKINIST (Trametinib) | Novartis | $173M | 12% | PEAK | Stable | 4.9yr |
| 2 | TAFINLAR (Dabrafenib) | Novartis | $147M | 11% | PEAK | Stable | 12.7yr |
| 3 | KEYTRUDA (Pembrolizumab) | Merck & Co. | $117M | 8% | PEAK | Growing | |
| 4 | BRAFTOVI (Encorafenib) | Pfizer | $87M | 6% | PEAK | Stable | 7.3yr |
| 5 | MEKTOVI (Binimetinib) | Pfizer | $57M | 4% | PEAK | Stable | 7.5yr |
Drug Class Breakdown
stable; represents legacy products and combinations
stable; BRAF/MEK standard-of-care entrenched
growing; expanding into adjuvant and combination settings
stable; combination partner in dual-targeted regimens
stable; resistance emergence driving combination strategies
declining; being replaced by PD-1 monotherapy and combinations
Career Outlook
StableMelanoma is a well-established oncology market with predictable patient populations, established treatment algorithms, and high-conviction clinical evidence. Career growth is driven by market expansion in adjuvant settings and emerging combination regimens rather than new mechanism discovery. Patent cliffs beginning 2031 will create opportunity for generic/biosimilar specialists but compress margins for innovators.
Breaking In
Join a commercial or clinical operations team at Novartis, Pfizer, or Merck to build oncology expertise in an established disease; this provides foundation for advancement into other solid tumors.
For Experienced Professionals
If you have melanoma expertise, consider roles in resistance mechanism research or adjuvant care expansion; alternatively, prepare transition strategy ahead of 2031 patent cliff via biosimilar, generics, or rare cancer focus.
In-Demand Skills
Best For
Hiring Landscape
Melanoma area hiring is concentrated in commercial roles (1,172 jobs, $257K avg) and clinical operations (259 jobs, $307K avg), reflecting a mature marketed market. Pfizer and Novartis are dominant melanoma employers but hiring across the broader company; R&D roles are available but primarily in early discovery rather than indication-specific development.
Top Hiring Companies
By Department
Commercial and clinical operations offer highest salary and volume; R&D hiring is competitive but fewer indication-specific roles given market maturity.
On Market (4)
Approved therapies currently available
Competitive Landscape
114 companies ranked by most advanced pipeline stage
+84 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 50 trials with date data
Clinical Trials (50)
Total enrollment: 22,124 patients across 50 trials
Integrated Pharmacokinetics (PK)/Efficacy, Safety, and Immunogenicity Study to Demonstrate Similarity of JPB898, a Proposed Biosimilar to Nivolumab, to Opdivo® in Combination With Yervoy®
A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma
Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma
A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma
A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
OH2 Injection in Melanoma
A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)
A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma
Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma
Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)
A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)
Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054)
Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma
Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma
Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma
Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006)
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab
Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck Cancer
GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma
Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma
CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy
A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma
Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267)
MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma
Nordic Adjuvant IFN Melanoma Trial
Contrast-enhanced Ultrasound for Sentinel Node Detection
Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma
SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron, MK-4031) vs. INTRON®A (SCH 30500, MK-2958) as Adjuvant Therapy for Melanoma (C98-135, MK-4031-002)
Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG)
PLUG-IN: Pembrolizumab Combined With Enfortumab Vedotin for Advanced Melanoma Patients
A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment
Neoadjuvant Intralesional Injection of Talimogene Laherparepvec
A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy
A Study of GC101 TIL in Advanced Melanoma
T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma
A Study of IBI363 in Subjects with Advanced Solid Malignancies
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
A Study of IBI363 in Subjects With Advanced Melanoma
A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma
A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma
Safety and Efficacy Study of QLF31907 in Advanced Melanoma and Urothelial Carcinoma
CD8 Minibody Repeatability Study
A Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma
A Trial of Intratumoural Tigilanol Tiglate in Adult Participants With Stage IIIB to IV M1c Melanoma
Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma
Perioperative Encobini in BRAFV600 Mutant Stage III (B/C/D) or Oligometastatic Stage IV Melanoma
Related Jobs in Oncology
Senior Oncology Account Specialist Melanoma Colorectal Cancer Columbia, SC
Chef(fe) produit marketing développement Klorane - Stage -H/F
Senior Director, Clinical Development Leader
Quality Control Microbiology Laboratory Supervisor
Responsable de secteur Avène Paris Nord/Est - CDD - H/F
Chef de projet IT - Web, Digital & CRM - CDI- F/H
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.